72
Participants
Start Date
September 3, 2019
Primary Completion Date
April 19, 2024
Study Completion Date
April 19, 2024
ASP9801
Administered by intratumoral injection
Pembrolizumab
Administered by Intravenous Infusion
Roswell Park Cancer Institute - Medical Oncology, Buffalo
University of Pittsburgh Medical Center, Pittsburgh
Fox Chase Cancer Center, Philadelphia
University of Maryland Medical Center, Baltimore
UVA Cancer Center, Charlottesville
VCU Massey Cancer Center, Richmond
University of Alabama at Birmingham, Birmingham
Norton Cancer Institute, Louisville
University of Kentucky, Markey Cancer Center, Lexington
Henry Ford Hospital, Detroit
University of Minnesota, Minneapolis
The University of Chicago Medical Center, Chicago
Nebraska Methodist Hospital, Omaha
Mary Crowley Cancer Research Center, Dallas
The University of Texas - MD Anderson Cancer Center, Houston
University of Arizona - Arizona Cancer Center, Tucson
The Angeles Clinic and Research Institute, Los Angeles
Merck Sharp & Dohme LLC
INDUSTRY
Astellas Pharma Global Development, Inc.
INDUSTRY